Regeneron Pharmaceuticals Reports Q2 2026 Financial Results

What Happened

• Regeneron Pharmaceuticals, Inc. announced on July 30, 2026 that it issued a press release reporting its financial and operating results for the quarter ended June 30, 2026. The press release is furnished with the Form 8-K as Exhibit 99.1. The Form 8-K was signed by Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary.

Key Details

• Filing date: July 30, 2026 (Form 8-K furnished to the SEC).
• Reporting period: Quarter ended June 30, 2026 (Q2 2026).
• Exhibit: Press release dated July 30, 2026 furnished as Exhibit 99.1 to the Form 8-K.
• The report was filed under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits).

Why It Matters

• This 8-K furnishes Regeneron’s quarterly results; the press release (Exhibit 99.1) contains the detailed earnings, revenue and operating metrics investors need to assess the company’s financial performance for Q2 2026.
• The filing does not report management changes, mergers, bankruptcies, or other material events beyond the quarterly results disclosure. Investors should review the Exhibit 99.1 press release for the specific figures and any commentary on business trends or guidance.